Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Négrier.C, et al. - The development of alloantibodies that inhibit the function of factor VIII (FVIII) or factor IX (FIX) is the most serious complication associated with the treatment of haemophilia. Bleeding events in patients with high-titre inhibitors generally cannot be managed with factor replacement therapy and require alternative strategies for haemostatic support


Previous Article Next Article

Today in Coagulation/Bleeding Dz...keeping you current

Thrombosis in childhood acute lymphoblastic leukaemia: epidemiology, aetiology, diagnosis, prevention and treatment
Best Practice & Research: Clinical Haematology , 06/12/09

The coagulopathy of acute promyelocytic leukaemia revisited
Best Practice & Research: Clinical Haematology , 06/18/09

JAK2V617F-Positive Latent Essential Thrombocythemia and Splanchnic Vein Thrombosis: The Role of Bone Marrow Biopsy for the Diagnosis of Myeloproliferative Disease
Acta Haematologica, 06/01/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address